Angiogenesis, the development of new blood vessels, is a fundamental physiological process that promotes embryonic development, tissue repair and fertility, yet that also promotes chronic inflammation, tumour growth and tumour metastasis 1 . New blood vessels in tumours can grow by sprouting from pre-existing vessels or by recruitment of rare, circulating bone marrow-derived endothelial progenitor cells [1] [2] [3] . Tumour cells, macrophages and fibroblasts within tumours can secrete factors, such as vascular endothelial growth factor (VEGF), that induce blood vessel growth in tumours 2, [4] [5] . Basic and clinical studies indicate that suppression of angiogenesis can inhibit tumour progression and metastasis 6 . Many lines of investigation implicate integrins, which are key regulators of endothelial cell migration and survival, as key regulators of tumour angiogenesis (FIG. 1) .
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. New blood vessels in tumours can grow by sprouting from pre-existing vessels or by recruitment of rare, circulating bone marrow-derived endothelial progenitor cells [1] [2] [3] . Tumour cells, macrophages and fibroblasts within tumours can secrete factors, such as vascular endothelial growth factor (VEGF), that induce blood vessel growth in tumours 2, [4] [5] . Basic and clinical studies indicate that suppression of angiogenesis can inhibit tumour progression and metastasis 6 . Many lines of investigation implicate integrins, which are key regulators of endothelial cell migration and survival, as key regulators of tumour angiogenesis (FIG. 1) .
Like angiogenesis, lymphangiogenesis -the growth of new lymphatic vessels -promotes tumour metastasis 2, [7] [8] [9] . The lymphatic system comprises a network of blindended, thin-walled lymphatic capillaries, collecting vessels and specialized secondary immune organs, including lymph nodes, tonsils, Peyer's Patches and the spleen. Lymphatic vessels drain protein-rich interstitial fluids and immune cells through the lymph nodes and return fluids back to the circulation at the thoracic duct. After entering lymph nodes, antigen-presenting cells such as dendritic cells may activate B-and T-cell immune responses. Tumour cells induce the growth of new lymphatic vessels within tumours and draining lymph nodes, enhancing dendritic cell trafficking to lymph nodes; increased lymphatic vessel density in tumours is also associated with increased metastasis to lymph nodes [7] [8] [9] . New findings indicate that select integrins can modulate lymphangiogenesis and may thereby affect tumour metastasis (FIG. 1) .
Angiogenesis and lymphangiogenesis can be stimulated by tumour-associated macrophages. Circulating bone marrow-derived cells (monocytes) migrate into tumours in response to tumour-secreted chemokines and differentiate into macrophages. Pro-angiogenic tumour macrophages release a number of potent proangiogenic cytokines, such as VEGFA, VEGFC, tumour necrosis factor α (TNFα), interleukin 8 (IL8) and basic fibroblast growth factor (bFGF, also known as FGF2) [4] [5] and express a broad array of extracellular matrix (ECM)-degrading proteases, including urokinase-type plasminogen activator (uPA, also known as PLAU), the matrix metalloproteinases MMP2, MMP7, MMP9 and MMP12, and elastase 4 . Importantly, new evidence suggests that macrophage infiltration can activate the angiogenic switch in spontaneous tumours 5 . Select integrins have key roles in regulating the trafficking of circulating monocytes and progenitor cells to tumours.
The integrin family of adhesion receptors
The integrin family is an extensive group of structurally related receptors for ECM proteins and immunoglobulin superfamily molecules. Integrins are divalent cationdependent heterodimeric membrane glycoproteins composed of non-covalently associated α and β subunits that promote cell attachment and migration on the surrounding ECM. Eighteen α and eight β subunits can 
Angiogenic switch
The induction of new blood vessel sprouting at an early time point in tumour development that leads to rapid, exponential tumour growth.
associate to form 24 unique integrin heterodimers. Each integrin subunit consists of an extracellular domain, a single transmembrane region and a short (~30-40 amino acids) cytoplasmic region 10 . Some integrins, such as α5β1, primarily recognize a single ligand, whereas others, such as αvβ3, can bind several ligands. Many integrins, including αvβ3, α5β1, αIIbβ3, αvβ6 and α3β1, recognize the tripeptide Arg-Gly-Asp (RGD) in their ligands 11 . Sequences flanking the RGD peptide are also important for integrin selectivity 12 . other integrins recognize alternative short peptide sequences; for example, integrin α4β1 recognizes Glu-Ile-Leu-Asp-Val (EILDV) and Arg-Glu-Asp-Val (REDV) in the alternatively spliced fibronectin domain known as IIICS 13 . Some integrins, such as α4β1, can also bind cell surface receptors, such as vascular cell adhesion molecule 1 (VCAM1), to promote cell-cell adhesion 14 
Integrin ligation promotes integrin clustering and subsequent integrin-mediated intracellular signal transduction. Unlike growth factor receptors, integrins have no intrinsic enzymatic or kinase activities, but activate complex signalling pathways by co-clustering with kinases and adaptor proteins in focal adhesion complexes. A number of signalling moieties are activated by integrins and many of these are found within focal adhesion complexes. Focal adhesion complexes are composed of integrins, protein kinases -such as focal adhesion kinase (FAK, also known as PTK2) and SRC -adaptor proteins such as Shc, signalling intermediates such as Rho family GTPases, actin-binding cytoskeletal proteins such as talin, α-actinin, paxillin, tensin and vinculin 15, 16 , and other signalling proteins. Integrin signalling promotes cell migration, proliferation and survival (BOX 2) . Loss of integrin ligation inhibits these events and unligated integrins can actively initiate apoptosis, even without loss of cell attachment. This form of cell death is stressresponse-and death-receptor-independent, but caspase 8-dependent, and has been called 'integrin-mediated death' 17 . In the past several years, some of the key molecular mechanisms that regulate angiogenesis and lymphangiogenesis have been delineated. Many lines of investigation implicate integrins as key regulators of endothelial cell migration and survival during these events. In this Review, we will discuss the evidence that supports roles for various integrins in the regulation of angiogenesis and lymphangiogenesis along with the status of integrinbased therapeutics for the treatment of cancer.
Integrins in angiogenesis
In vitro and in vivo data have implicated a number of endothelial cell integrins in the regulation of cell growth, survival and migration during angiogenesis. These integrins include the heterodimers α1β1, α2β1, α4β1, α5β1, α6β1, α6β4, α9β1, αvβ3 and αvβ5 (TABLE 1) . Additionally, the glial cell integrin αvβ8 regulates blood vessel development in the brain 18 . Distinct experimental approaches, such as inhibition of angiogenesis by antagonists, knock-in mutations and genetic deletions in ovo, have led to conflicting theories of the roles of several integrins in angiogenesis, including αv integrins and α2β1 integrin (discussed below). However, increasing molecular evidence in vivo points to major roles for key integrins in tumour angiogenesis.
αv integrins. The αv integrin subunit can heterodimerize with several different β subunits (β1, β3, β5, β6 and β8) to achieve unique ligand-binding profiles. The integrin αvβ3, a receptor for RGD-containing proteins such as vitronectin, fibronectin, fibrinogen and osteopontin (encoded by SPP1), which are components of the ECM, was the first of the αv integrins to be characterized 19 . Integrin αvβ3 was the first αv integrin to be shown to regulate angiogenesis 20 . This integrin is widely expressed on blood vessels in human tumour biopsy samples but not on vessels in normal human tissues. Its expression on endothelial cells is stimulated by angiogenic growth factors such as bFGF, TNFα and IL8 and it is upregulated on endothelium in tumours, wounds and sites of inflammation 20 . Whereas angiogenesis during wound healing is tightly regulated and self-limiting, angiogenesis associated with chronic inflammation and cancer is often persistent and abnormal 1 . However, many of the same molecules that regulate angiogenesis in wound healing, such as integrin αvβ3, also regulate pathological angiogenesis. Increasing evidence points to important causative links between inflammation and cancer and some evidence suggests that inflammation promotes the angiogenic switch in tumours [4] [5] 
Several experimental approaches indicate that αvβ3 has a key role in endothelial cell survival and migration during angiogenesis [20] [21] . Integrin αvβ3 is expressed in response to angiogenic growth factors and tumours
At a glance
• Angiogenesis and lymphangiogenesis have important roles in cancer progression:
angiogenesis, the growth of new blood vessels, promotes tumour growth and tumour metastasis, and lymphangiogenesis, the growth of new lymphatic vessels, promotes tumour metastasis. Angiogenesis and lymphangiogenesis are regulated by integrins, which are members of a family of cell surface adhesion receptors.
• The integrin family is an extensive group of structurally related receptors for extracellular matrix proteins and immunoglobulin superfamily molecules. Integrin ligation promotes intracellular signal transduction, cell migration and survival in angiogenesis and lymphangiogenesis.
• A number of endothelial cell integrins regulate angiogenesis in diverse manners, including integrins α1β1, α2β1, α4β1, α5β1, α9β1 and α6β4. αv integrins are also important in angiogenesis, although the exact nature of these roles is hotly disputed. Expression and function analysis of αv integrins in wild-type animals using integrin antagonists as well as analysis of knock-in mutant mice indicate that αv integrins promote angiogenesis, whereas genetic deletion studies suggest that αv integrins are not required for angiogenesis.
• Although less is known about the integrins that regulate lymphangiogenesis, integrin α9 is required for normal developmental lymphangiogenesis. Integrins α4β1, α2β1 and α1β1 have also been implicated in the regulation of tumour lymphangiogenesis.
• Integrins on bone marrow-derived myeloid cells can also promote angiogenesis. Circulating bone marrow-derived cells migrate into tumours in response to tumoursecreted chemokines and cytokines and integrins α4β1 and αMβ2 (CD11b) have key roles in this process, indirectly influencing tumour angiogenesis.
• Antagonists of several integrins, including αvβ3, αvβ5 and α5β1, are currently under investigation as clinical agents to suppress tumour angiogenesis and growth either alone or in combination with current cancer therapeutics. Nature Reviews | Cancer 
Lymph node metastasis

Chick chorioallantoic membrane
A thin, highly vascularized fetal membrane formed by fusion of the chorion and allantois in fertilized chicken eggs that is often used to evaluate pro-and anti-angiogenic agents.
Choroidal angiogenesis
The development of new blood vessels in the highly vascular area of the eye that lies between the retina and the sclera.
in chick chorioallantoic membrane, mouse, rabbit and human models of angiogenesis and tumour growth [20] [21] [22] [23] . Antagonists of αvβ3 inhibited angiogenesis and tumour growth in a variety of animal models of cancer and blocked corneal as well as choroidal angiogenesis in animal models of ocular disease [20] [21] [22] [23] [24] [25] . Inhibition of αvβ3 function in quail embryos disrupted vasculogenesis by blocking lumen formation and disturbing vascular patterning 26 . Integrin αvβ3 antagonists induce endothelial cell apoptosis, increase the activity of the tumour suppressor p53, increase levels of the cell cycle inhibitor p21
(encoded by CDKN1A) and decrease levels of the antiapoptotic protein BAX (BCL2-associated X protein) 27 . Further studies show that αvβ3 antagonists activate a caspase 8-dependent cell death program 28 . Thus, a sizeable body of evidence indicates that integrin αvβ3 promotes angiogenesis and endothelial cell survival and that antagonism of this integrin suppresses angiogenesis by inducing endothelial cell apoptosis in vitro and in vivo. Ligation of endothelial αvβ3 integrin has also been shown to activate mitogen-activated protein kinase (MAPK), FAK and Src, among other kinases, resulting in cell proliferation, differentiation and migration 29 . The related integrin αvβ5 promotes an angiogenic pathway that is distinct from that regulated by αvβ3. Anti-αvβ3 antibodies blocked angiogenesis induced by bFGF, whereas antibodies that target αvβ5 blocked the angiogenesis induced by VEGF in both the rabbit Figure 1 | Mechanisms regulating angiogenesis and lymphangiogenesis. a | Tumour cells near pre-existing blood vessels secrete growth factors and chemokines, such as vascular endothelial growth factor A (VEGFA), basic fibroblast growth factor (bFGF) and tumour necrosis factor α (TNFα), that stimulate quiescent vascular endothelium to enter the cell cycle. Tumours also secrete factors such as VEGFC, VEGFA or hepatocyte growth factor (HGF) that stimulate the growth of new lymphatic vessels in the peritumoural space. b | These growth factors activate or upregulate expression of integrins such as α1β1, α2β1, α4β1, α5β1 and αvβ3 on blood vessels and α4β1, α9β1, α2β1 and α1β1 on lymphatic vessels. Tumour-derived VEGFC also promotes new lymphatic vessel growth in draining lymph nodes. c | These integrins then promote endothelial cell migration and survival during invasion of tumour tissue, resulting in the creation of new vessel sprouts. The new blood vessels promote tumour growth by removing waste products and providing nutrients. These new blood and lymphatic vessels also provide an avenue for tumour metastasis. d | Lymphangiogenesis promotes metastasis to lymph nodes and, sometimes, more distant tissues such as lung, whereas angiogenesis promotes metastasis to local and distant sites, such as lung. ECM, extracellular matrix. Nature Reviews | Cancer Cytoplasm corneal eye pocket and the chick chorioallantoic membrane assay 23 . The VEGF-αvβ5 pathway, but not the bFGFαvβ3 pathway, is dependent on Src kinase and protein kinase C 30 . In vivo angiogenesis assays showed that bFGF and TNFα depend on αvβ3 to initiate angiogenesis, whereas αvβ5 is required for TGFα-and VEGF-mediated angiogenesis. These data indicate unique roles for αvβ3 and αvβ5 integrins in angiogenesis and suggest that both could be important therapeutic targets. Some pathological conditions might depend on αvβ5 whereas others might depend on αvβ3. For example, integrin αvβ5 is more prevalent on cerebral cavernous malformations than is integrin αvβ3 (REF. 31 ). Additionally, only VEGF, which acts through αvβ5, rather than bFGF, which acts through αvβ3, promotes survival of developing retinal vessels 32 as well as vascular permeability [33] [34] . As vascular permeability promotes tumour metastasis [33] [34] , these results suggest that integrins that promote vascular permeability, such as αvβ5, may also promote tumour metastasis.
In contrast to the roles that are indicated by expression and function analysis, studies of integrin β3 (Itgb3)-null mice suggest that this integrin is not absolutely required for vascular development 35 . Although half of integrin β3-null mice survive embryogenesis, the other half die in utero, exhibiting intrauterine bleeding or defective placental development 35 . These mice exhibit apparently normal vessels in the brain and gut, as well as normal post-natal retinal neovascularization. However, male mice lacking β3 integrin exhibit coronary capillaries of irregular endothelial thickness, with endothelial protrusions into the lumen, and expanded cytoplasmic vacuoles 36 . These defective coronary vessels can be normalized by administration of inhibitors of VEGF or VEGF receptor 2 (VEGFR2, also known as KDR), suggesting that enhanced VEGF signalling might compensate for the loss of β3 integrin 36 . In fact, β3-null mice exhibit enhanced tumour angiogenesis compared with normal mice 37 , with strongly upregulated VEGFR2
Box 1 | Regulation of integrin activation
Integrin activity during angiogenesis can be modulated by integrin expression or by growth factor or chemokine receptor signalling, which alters integrin conformation ('insideout' signalling). Crystallography, NMR and electron microscopy studies suggest that the globular region formed by the amino-termini of the α and β chains is bent towards the membrane and the cytoplasmic regions of the two subunits are closely associated with one another in an inactive integrin [115] [116] [117] [118] (see figure, left panel). Integrin activation is associated with an unbending and elongation of the dimer and separation of the cytoplasmic domains [115] [116] [117] [118] [119] [120] (see figure, right panel). This allows interaction of integrin cytoplasmic domains with intracellular proteins and permits integrin-mediated signal transduction 120 . Once activated, integrins bind ligands, cluster and initiate their own signalling cascades that lead to cell migration and survival. The activity of many endothelial cell integrins during angiogenesis is regulated primarily at the transcriptional level. The expression of integrins α1β1, α2β1, α4β1, α5β1 and αvβ3 is strongly induced by pro-angiogenic growth factors or chemokines [20] [21] [22] [23] 67, 73 . However, other integrins are activated by receptormediated signalling. Integrin αvβ5 is constitutively expressed on vascular endothelium, yet is only functionally activated by vascular endothelial growth factor receptor 2 (VEGFR2)-mediated signal transduction 31 . In circulating cells such as monocytes and other leukocytes, integrins are generally inactive until cells are stimulated by chemokines, hormones or other factors. For example, integrin α4β1 activity on leukocytes can be stimulated by chemokine signalling 121 . Additionally, integrin αIIbβ3 is inactive on resting platelets but becomes activated from within when an external stimulus such as thrombin or adrenaline binds a cell surface receptor and induces the conformational change in the integrin cytoplasmic domains. It then binds its ligand fibrinogen, leading to platelet aggregation 122 . Thus, roles of integrins in angiogenesis can be controlled either by expression or by intracellular signalling (inside-out signalling). Thus, in tumours, the expression of VEGF and other pro-angiogenic factors can continuously stimulate integrin expression and activity and stimulate unregulated angiogenesis. A schematic representation of the structure of an inactive and active integrin is shown. BTD, membrane-proximal β tail domain; PSI, structural modules found in plexins, semaphorins and integrins. Adapted, with permission, from REF. 115  Annual Reviews (2005). Nature Reviews | Cancer . Taken together, these studies suggest that compensatory VEGFR2 signalling changes may have a role in the survival of integrin β3-deficient animals. In contrast to β3-null mice, integrin αvβ5-null mice exhibit completely normal development and normal angiogenesis 39 , indicating that this integrin is not required for vascular development.
Genetic ablations of the αv subunit (encoded by Itgav), which eliminate expression of integrins αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8 suggest that, in some mice, αv integrins are not required for blood vessel development in most tissues. Twenty percent of embryos lacking αv integrins survive to birth with normal blood vessels in many tissues. However, 80% of mice die in utero between E10.5 and E11.5 with defective placental blood vessels 40 .
The remaining 20% of αv-null mice die shortly after birth with severe brain and intestinal haemorrhage, with
Box 2 | Integrin regulation of cell migration and focal adhesions
Integrins 'integrate' signals from the extracellular matrix (ECM) to the intracellular cytoskeleton in focal adhesions. Integrins have short cytoplasmic tails and no intrinsic enzymatic or kinase activities. To integrate signals and activate intracellular signalling pathways, integrins co-cluster with serine, threonine and tyrosine kinases, phosphatases and adaptor proteins in focal adhesions. Focal adhesion complexes are composed of integrins, protein kinases such as focal adhesion kinase (FAK), Src and many other kinases, adaptor proteins such as Shc, signalling intermediates such as phosphatidylinositol-3 kinase, Rho and Rac GTPases and actin-binding cytoskeletal proteins such as talin, α-actinin, paxillin, tensin and vinculin [15] [16] . Integrin signalling promotes cell migration by providing traction along the ECM and by promoting actin remodelling through the Rho family small GTPases. This actin remodelling leads to cytoplasmic flow in the direction of cell migration and cell body retraction at the trailing end of the cells. Individual components of integrin-mediated signalling cascades, such as FAK, Shc and Raf, have essential roles in angiogenesis. For example, FAK is a mediator of signal transduction by integrins and growth factor receptors in endothelial cells. Overexpression of FAK in mice promoted angiogenesis 123 . By contrast, conditional deletion of PTK2 (which encodes FAK) in endothelial cells led to defective angiogenesis in the embryos, yolk sac and placenta, impaired vasculature and associated haemorrhage, oedema and developmental delay, and late embryonic lethality 124 . In addition, in vitro deletion of FAK in endothelial cells isolated from Fak Flox/Flox mice exhibited reduced tube formation, cell survival, proliferation and migration in vitro 124 . These results indicate that FAK has a crucial role in angiogenesis and vascular development. In addition, Shc, an important adaptor protein that potentiates mitogen-activated protein kinase (MAPK) pathway signalling is activated by both integrins and growth factor receptors and has crucial roles in early vascular development. Shc is primarily expressed during early mouse development in the developing heart and endothelium 125 . Shc-null animals died between embryonic day (E)10.5 and 11.5 with defects in heart and blood vessel development and isolated Shc-null cells exhibited migration deficiencies 125 . Like Shc, RAF1 is an integral component of the MAPK signalling pathway. This signalling intermediate is activated by integrins and is crucial for vascular morphogenesis 126 . Mice null for Raf1 die during early development by E11.5 with vascular defects in the yolk sac, placenta and head 126 . Thus, integrin-mediated signalling probably has important roles in vascular development in adult angiogenesis. A schematic representation of integrin signalling and focal adhesion components is shown. GRB2, growth factor receptor-bound protein 2; MEK, MAPK kinase; MLCK, myosin light chain kinase.
distended and leaky vessels in these tissues 40 . Thus, αv integrins appear to have key roles in embryonic development of blood vessels in tissues such as placenta and brain. Surprisingly, brain blood vessels developed normally in mice with Tie2-Cre-mediated endothelial cellspecific deletion of αv integrins, but not in mice with Nestin-Cre-and GFAP-Cre-mediated embryonic central nervous system deletion of αv integrins 41 . Mice null for integrin β8 (encoded by Itgb8) also exhibited brain blood vessel defects similar to αv-null mice 18 . Together, these studies indicate that glial cell αvβ8 integrin is required for proper brain blood vessel development. The brain blood vessels of mice lacking integrin αv or β8 subunits exhibit enlarged, disrupted blood vessels, with defective apposition of glial and endothelial cells 18, 42 . Interestingly, these studies suggest that glial cell integrins may have roles in establishing or maintaining the blood-brain barrier.
Results from studies of integrin antagonists indicate that αv integrins promote angiogenesis, whereas genetic deletion studies indicate that αv integrins are not required for angiogenesis. one hypothesis to explain this conflict is that αv integrins act as negative regulators of angiogenesis; once they are deleted in development, angiogenesis occurs at an accelerated rate. An alternative hypothesis is that animals lacking αv integrins develop compensatory changes in VEGF signalling that permit angiogenesis to occur during embryogenesis. New studies bring clarification to the much-disputed role of this integrin in angiogenesis. Importantly, knock-in mutant animals expressing the point mutations Y747F and Y759F in the integrin β3 cytoplasmic tail developed normally, but exhibit reduced growth factor-and tumour-induced angiogenesis in vivo 43 . Mutant endothelial cells exhibit impaired adhesion, spreading, migration and tube formation, as well as impaired complex formation between VEGFR2 and β3 integrin 43 . These results provide genetic evidence that integrin β3 has an important role in promoting angiogenesis 43 . Together, these diverse results can be interpreted to indicate that integrin αvβ3 has an important role in angiogenesis and that loss of expression of this integrin in development can be partially compensated for by upregulation of other angiogenesis signalling pathways.
How does integrin αvβ3 modulate angiogenesis? Unligated or antagonized αvβ3 integrin can inhibit cell survival. In a three-dimensional collagen matrix, αvβ3-bearing cells undergo apoptosis and cells deficient in αvβ3 survive longer 44 . As intact collagen is not a ligand for αvβ3, these studies indicated that unligated integrin αvβ3 provides a stimulus for apoptosis. This unligated integrin-mediated cell death is caspase 8-dependent and is sometimes called 'integrin-mediated death' 28 . Functioning as a biosensor, αvβ3 may promote angiogenesis in the ligated state, but when ligands are absent or ligand binding is antagonized, αvβ3 may activate a death pathway to inhibit angiogenesis.
Thus, depending on the microenvironment and the ligation state, integrins promote or inhibit angiogenesis by positively or negatively regulating cell survival. Integrin αvβ3 appears to function as a regulator of angiogenesis by balancing opposing signals in the tumour microenvironment. 
Posterior somites
Cuboidal, segmented masses of mesoderm organized in pairs and distributed along the developing neural tube. Posterior somites give rise to the thoracic, lumbar and sacral vertebrae.
Fibronectin-binding integrins.
Fibronectin is a key ECM protein that is deposited by endothelial cells during normal 45 and tumour 46 angiogenesis. Short fibronectin peptide loops containing the sequence Arg-Gly-Asp (RGD) interact with integrins such as α5β1, αvβ5 and αvβ3 (REF. 11). Fibronectin secreted by endothelial cells also contains the alternatively spliced EIIIA, EIIIB and IIICS domains, which bind to integrins α4β1 and α9β1 (REFS 13, 47) . Fibronectin is essential for developmental angiogenesis as early embryonic lethality -due to yolk sac and other mesodermal tissue defects -occurs when all isoforms of fibronectin are deleted 48 . Deletion of only EIIIA and EIIIB alternatively spliced variants is also embryonic lethal, owing to severe vascular defects that suppress placentation, yolk sac vessel formation and heart formation 49 . Thus fibronectin has a key role in angiogenesis, as do many of its receptors, the β1 integrins.
Genetic ablation studies have demonstrated the crucial role of β1 integrins in angiogenesis and vascular development. β1-integrin (Itgb1)-null embryos die by embyronic day (E)9.5-10.5 in utero owing to implantation defects [50] [51] . However, animals with an endothelial cell-specific deletion of β1 integrin (Tie2-Creβ1 floxed mice) die by E10.5 with severe vascular defects 52 . Integrin β1-null teratomas grown in wild-type hosts develop small host-derived vessels but no Itgb1-null vessels 53 . Furthermore, endothelial cell proliferation and vessel branching is absent in Itgb1-null embryoid bodies 53 . Thus, the β1 integrin family clearly has a key role in angiogenesis.
Integrin α5β1 is poorly expressed on quiescent endothelium but its expression is significantly upregulated on endothelium during tumour angiogenesis in both mice and humans 46 . Expression of this integrin is also upregulated during corneal angiogenesis 54 . Integrin α5β1 expression is induced in response to a variety of angiogenic stimuli, such as bFGF, IL8 and the ECM protein DEL1 (also known as EDIL3), but not by VEGF 46, 55 . Current evidence suggests that the activity of this integrin in angiogenesis is regulated by transcription 55 . Indeed, expression of α5β1 in endothelial cells is regulated by a homeobox family transcription factor, HoXD3, which is itself induced in response to bFGF and other stimuli but not by VEGF 55 . HOXD3 antisense suppresses integrin α5β1 expression in vitro and in vivo and overexpression of HoXD3 upregulates α5β1 expression 55 . Antagonists of α5β1 inhibited tumour 46 , corneal 54 and choroidal 56 angiogenesis in chicks and mice, thus leading to inhibition of tumour growth or tumour regression. Integrin α5β1-mediated adhesion promotes endothelial cell migration and survival in vivo and in vitro by suppressing the activity of protein kinase A (PKA) [57] [58] . Activation of PKA by expression of the catalytic subunit of PKA or by exposure of cells to cAMP or forskolin directly inhibits cell migration and stimulates apoptosis in vitro and in vivo. Thus, integrin α5β1 promotes endothelial cell survival during angiogenesis.
Embryonic deletion of the integrin α5 subunit induces early mesenchymal abnormalities, leading to lethality of α5 (Itga5)-null embryos 59 . Embryos lacking integrin α5 have a truncated posterior and lack posterior somites. These embryos also exhibit abnormal organization of the emerging extra-embryonic and embryonic vasculature, and reduced complexity of the emerging vasculature 59 . Further studies using α5-null ES cells to grow teratocarcinomas showed decreased proliferation, increased apoptosis and decreased vascularization in teratocarcinomas derived from α5-null ES cells compared with controls 60 . In vitro growth of embryoid bodies lacking α5 integrins showed a delay and reduction in the formation of the early vascular plexus and formation of complex vascular structures 61 . Together, these data indicate a key role for α5β1 in vasculogenesis and angiogenesis.
Integrin α4β1, another important fibronectin receptor, is best known as a lymphocyte integrin involved in adhesion and extravasation of lymphocytes by binding to
Box 3 | The links between inflammation, wound-healing and cancer
Inflammation is increasingly thought to be important in tumour initiation, progression and metastasis 127 . Inflammation is caused by tissue injury, ischaemia, toxins and other damaging stimuli. Injured tissues release chemokines and growth factors that attract leukocytes and upregulate adhesion molecules on the surface of endothelium in injured tissues to promote wound-healing. When the release of these factors is chronic, invasion of leukocytes into tissues is sustained and the further release of chemokines and other factors can induce oxidative damage, DNA mutations, tumour development, tumour angiogenesis and lymphangiogenesis and subsequent metastasis. A key example is the increased risk of developing colon carcinoma in patients with chronic inflammation such as inflammatory bowel disease 127 . Substantial evidence supports the role of inflammation in tumour angiogenesis. The number of macrophages in tumour tissues is significantly greater than in normal tissues 121, 122 . Importantly, high tumourassociated macrophage (TAM) densities indicate poor prognoses in breast, prostate, ovarian and cervical cancer [128] [129] [130] [131] [132] [133] . TAMs promote neovascularization by releasing potent pro-angiogenic cytokines and growth factors, such as VEGF, tumour necrosis factor α (TNFα), interleukin 8 (IL8) and basic fibroblast growth factor (bFGF) [134] [135] [136] . Additionally, TAMs also express a broad array of proteases known to have roles in the angiogenic process. These proteases include urokinase-type plasminogen activator and the matrix metalloproteinases MMP2, MMP7, MMP9 and MMP12 that remodel and degrade the extracellular matrix. Tumours produce factors such as monocyte chemoattractant protein 1 (MCP1, or CCL2) and RANTES (also known as CCL5) that increase the infiltration of TAMs in several primary tumours including breast, ovarian, melanoma and glioblastoma [141] [142] [143] . Besides stimulating tumour angiogenesis and lymphangiogenesis, inflammatory chemokines, such as IL6, or their regulators, such as IKKβ (also known as IKBKB) and IKKα (also known as CHUK), also promote tumour progression to malignancy by directly stimulating tumour cell activation or cancer stem cell proliferation [144] [145] [146] [147] [148] [149] .
Pericyte
A mesenchymal cell precursor to vascular smooth muscle that associates with endothelial cells during angiogenesis and provides support to small capillaries.
Hemidesmosome
An organized adhesive structure on the surface of epithelial cells comprising integrin α6β4 attached on the exterior of the cell to laminin and on the interior of the cells to plectin and cytosolic keratins.
VCAM1, a member of the immunoglobulin superfamily, expressed on inflamed endothelial cells. This integrin can bind both IIICS fibronectin and VCAM1. Loss of integrin α4 (Itga4) during development leads to defects in placentation, heart development and coronary artery development, causing lethality between E10.0 and E12.0 (REF 62) . However, owing to the severe heart defects, it is not clear whether α4β1 has a role in developmental angiogenesis.
Nevertheless, recent studies showed that integrin α4β1 is expressed on neovessels in murine and human tumours and in response to VEGF, bFGF, IL1β and TNFα
63
. Antagonists of this integrin blocked tumour neovascularization and decreased tumour growth in chick and murine models of tumour growth 63 . This integrin promotes adhesion of endothelium with VCAM1-expressing vascular smooth muscle cells during blood vessel formation and antagonists of α4β1 induced cell death of both endothelial cells and pericytes
. Transient but direct contact between endothelial cells and pericytes during angiogenesis appears to have an important role in cell survival signalling in each cell type, although the exact signalling mechanisms remain unknown. As endothelial cells express the pericyte chemoattractant platelet-derived growth factor (PDGF) and pericytes express VEGF, it is possible that close proximity of the two cell types facilitated by integrin α4β1-VCAM1 interactions allows each cell type to respond to growth and survival signals emanating from the other cell type 63 . Thus, integrin α4β1-VCAM1-dependent cell-cell attachment promotes the survival of both endothelial cells and pericytes during angiogenesis.
The most recent fibronectin-binding integrin to be found to have a role in angiogenesis is integrin α9β1 (REF. [64] [65] [66] [67] . This interesting integrin is structurally similar to integrin α4β1 but, unlike α4β1, it is a receptor for a number of ECM proteins and cell surface receptors including tenascin C, thrombospondin, osteopontin, IIICS fibronectin, VCAM1 and other ligands [64] [65] [66] [67] . Integrin α9β1 is expressed on epithelia, osteoclasts, smooth muscle cells and also endothelial cells. Recent studies show that this integrin promotes VEGFA-stimulated angiogenesis by a unique mechanism: it directly binds VEGFA and blocking antibodies to α9β1 suppress VEGFA-induced angiogenesis 64 . However, other studies found that α9β1 binds directly to the N terminus of thrombospondin and blocking antibodies to α9β1 inhibited angiogenesis induced by this thrombospondin fragment 65 . Integrin α9β1-null mice die 8-12 days after birth owing to lethal defects in development of the lymphatic system; however, they do not exhibit obvious defects in development of blood vessels 68 . Fibronectin and several of its receptors clearly have central roles in promoting angiogenesis during development and during tumour growth. However, additional integrin subfamilies, such as the laminin family, also regulate angiogenesis, as described below.
Laminin-binding integrins. Similar to integrins αvβ3 and αvβ5, results of studies of the expression and function of the laminin and collagen-binding integrins α1β1 and α2β1 differ from in ovo genetic deletions. In normal animals, VEGFA treatment upregulates expression of both α1β1 and α2β1 on vascular endothelial cells 69 . Function-blocking antibodies directed against both integrins reduced VEGFA-induced angiogenesis in vivo and reduced tumour growth and angiogenesis 69 . However, integrin α1-null (Itga1 -/-) mice and α2-null (Itga2 -/-) mice are viable and fertile, indicating that these integrins are not required for angiogenesis in developing embryos. Tumours grown in α1β1-deficient mice grew more slowly and exhibited less angiogenesis, indicating an important role for this integrin in angiogenesis 70 . However, mice lacking α2β1 integrins exhibit increased melanoma (derived from B16F10 cells) growth and angiogenesis when compared with wild-type mice 71 . By contrast, Lewis lung carcinoma (LLC) tumours did not exhibit increased angiogenesis or growth in α2-null mice. Enhanced angiogenesis was attributed to an increase in VEGFR1 expression and function on α2-null endothelial cells. Whereas B16F10 melanoma cells expressed high levels of the VEGFR1-binding growth factor PLGF (placental growth factor, also known as PGF), levels expressed by LLC cells were low. Upon transfection with PLGF, LLC tumours grew more rapidly in α2β1-null animals than in wild type, suggesting that compensatory changes in growth factor expression and signalling can occur in animals with null mutations 71 . Integrins α1β1 and α2β1 appear to have important roles in tumour angiogenesis, although complete understanding of their roles is still developing.
The α6 integrin subunit can form heterodimers with either the β1 or the β4 subunit. Integrin α6β1 is expressed at high levels in capillary endothelial cells in vivo 72 . Antibody inhibitors of α6 integrin prevented endothelial cell tube formation in vitro, suggesting a role for α6 in the angiogenic process 72 . Endothelial cell migration and tube formation was also blocked by downregulation of α6 expression in brain microvascular endothelial cells with small interfering RNA 72 . Histological analysis reveals that the β4 subunit is expressed on human and murine tumour endothelium 73 . In addition, the α6β4 ligand, laminin 5, is also expressed by tumour blood vessels 73 . However, mice that are null for the β4 or the α6 subunit do not exhibit overt vascular defects but die immediately after birth, in part owing to severe skin blistering caused by passage through the birth canal [74] [75] [76] . In stably adherent cells, the β4 integrin mediates hemidesmosome assembly 76 . However, in growth factorstimulated cells, hemidesmosomes do not form and the β4 subunit cytoplasmic tail is tyrosine phosphorylated in response to receptor tyrosine kinase activation of the Src family kinases. Upon phosphorylation of Tyr1440 and Tyr1422, the β4 subunit interacts with the SH2 domain of Shc, promoting Raf-ERK (extracellular signal-regulated kinase) and Rac-JNK (Jun N-terminal kinase, also known as MAPK8) signalling and immediate early gene expression 77 . Mice with a targeted deletion of the carboxyterminal portion of the β4 subunit cytoplasmic tail (∆1355) developed normally, but adult mice exhibited a reduced angiogenic response to bFGF and VEGFA 73 . Nature Reviews | Cancer 
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Endosomes or granules in platelets that contain growth factors such as VEGF, TGFβ and PDGF.
Spontaneous tumour growth in these animals was also reduced, as was tumour angiogenesis. Integrin α6β4 did not affect proliferation of endothelial cells but was required for endothelial cell adhesion and migration. In addition, endothelial cell-specific loss of β4 integrin suppressed nuclear translocation of phospho-ERK and nuclear factor κB (NFκB) 73 . These studies suggest that integrin α6β4 is a novel target for anti-angiogenic therapies.
Integrin α6β1 is also expressed on endothelium; its expression can be confirmed by immunoprecipitation 72 . Unlike α6β4, which shows a preference for laminin 5, integrin α6β1 binds most laminin isoforms as well as other ECM proteins including CYR61, thrombospondin 1 and thrombospondin 2 (REF. 78 ). As α6 integrin antagonists and α6 small interfering RNA constructs inhibit angiogenesis, it is possible that integrin α6β1 promotes angiogenesis. However, as these agents can block the function of both integrins α6β1 and α6β4, it is not yet clear what part integrin α6β1 plays in tumour angiogenesis.
The studies described here show that endothelial cell integrins that bind to diverse ECM ligands promote angiogenesis during embryonic development and tumour growth. Embryonic deletion of many of these integrins does not lead to an embryonic lethal phenotype, indicating that many integrins have overlapping functions during development. However, as antagonism or deletion of these integrins suppresses tumour angiogenesis, each integrin can contribute to angiogenesis in at least some tumour microenvironments.
Integrins on bone marrow-derived cells
Integrins on bone marrow-derived immune cells can also promote angiogenesis by facilitating myeloid cell and endothelial progenitor cell homing to tumours (FIG. 2) . Circulating bone marrow-derived cells migrate into tumours in response to secreted chemokines and cytokines. Monocytes can then differentiate into proangiogenic secreting macrophages. Myeloid cells express a number of functional integrins (α2β1, α4β1, α5β1, αvβ3, αvβ5, αMβ2 (CD11b or ITGAM) and αXβ2 (CD11c)). A subset of these integrins regulate extravasation of these cells from the blood stream and their migration within neovascular microenvironments.
Recent studies indicate that integrin α4β1, a receptor for VCAM and fibronectin containing the CS1 region, selectively promotes the homing of both endothelial progenitor cells and monocytes to neovascular tissue [79] [80] . Human CD34 + and murine LIN -/SCA1 + progenitor cells as well as human and murine bone marrow-derived myeloid cells (CD14 + / CD11b + ) adhered to endothelial cells in vitro and to tumour endothelium in vivo through integrin α4β1 . Treatment of mice bearing LLC tumours with antagonists of integrin α4β1 significantly suppressed the number of monocytes and progenitor cells found within tumours and reduced blood vessel density 79, 80 . These studies suggest that the suppression of monocyte and progenitor cell homing to tumours by integrin α4β1 antagonists could be a useful supplementary approach to suppress tumour angiogenesis and growth.
other integrins can also mediate homing of precursor cells to sites of neovascularization. The adhesion of circulating endothelial precursor cells to endothelial monolayers was shown to be integrin β2-dependent.
Haematopoietic progenitor cells (LIN -/SCA1
+ cells) from β2-integrin-deficient mice exhibited reduced homing to sites of ischaemia 81, 82 . Together, these studies identified key functions for integrins during precursor cell and/or monocyte homing to angiogenic sites.
The platelet integrins αIIbβ3 and α2β1 may indirectly regulate angiogenesis by promoting platelet deposition within tumours and damaged tissues. Platelets release several pro-angiogenic factors, which are stored in alpha granules, such as VEGFA, SDF1 (also known as CXCL12) and sphingosine-1-phosphate, suggesting that integrins on platelets may also have roles in angiogenesis 83, 84 . Thus, integrins on bone marrow-derived cells can have key roles in angiogenesis.
Integrins in lymphangiogenesis
Lymphatic vessels form a network that drains fluid and cells from tissues; these vessels are required for tissue homeostasis. Lymphatic capillaries are lined by loosely associated endothelial cells without a covering of pericytes or vascular smooth muscle. This structure allows ready passage of immune cells and tumour cells into the lymphatic system. Indeed, lymph nodes are typically the first organ to exhibit tumour metastasis, and sentinel node monitoring is used extensively to detect metastases. Until recently, analysis of the role of lymphatics in tumour growth and metastasis had been hindered by the absence of lymphatic markers. Recent identification of specific lymphatic markers, such as the transcription factor PRoX1 and the CD44 homologue lymphatic vessel hyaluronan receptor 1 (LYVE1) 85, 86 , has made it possible to study mechanisms regulating lymphangiogenesis. The growth factors VEGFC and VEGFD (also known as FIGF), which can be expressed by tumour cells or macrophages in tumours, promote growth of the lymphatic vessel network by activating the lymphatic endothelial cell receptor VEGFR3 (also known as FLT4) (REF 87) .
Evidence is mounting regarding roles for integrins in lymphangiogenesis (FIG. 1) . Integrin α9β1 is required for the development of the fully functional lymphatic system: mice deficient in α9β1 integrin die 6-12 days after birth due to chylothorax: an accumulation of lymph in the pleural cavity 68 . Integrin α9β1 has a role in growth factor-mediated lymphangiogenesis as PRoX1, a lymphatic endothelial cell-selective transcription factor, coordinately upregulates integrin α9β1 and VEGFR3 expression and endothelial cell motility in vivo 88 . Recent studies show that this integrin promotes VEGFC-and VEGFD-stimulated cell migration by directly binding these growth factors 89 . Importantly, antagonism of α9β1 suppresses VEGFC-induced motility. Taken together, these studies indicate that α9β1 has unique and crucial roles in lymphangiogenesis.
other studies have shown that integrins α1β1 and α2β1 are expressed on lymphatic endothelium in healing wounds in response to VEGFA. Inhibition of these integrins blocked lymphangiogenesis in these wounds 90 . Integrin α5β1 is expressed by a subpopulation of lymphatic vessels in the inflamed cornea and small-molecule antagonists of this integrin inhibited inflammatory lymphangiogenesis 91 . Integrin α4β1 is highly expressed on tumour lymphatic endothelium 92 and antagonists of this integrin can block lymphangiogenesis and tumour metastasis. By contrast, αv integrins appear to have little or no role in lymphangiogenesis and integrin α5β1 appears to play no part in tumour lymphangiogenesis 92 . Thus, several integrins appear to be important in lymphangiogenesis, yet the profile of integrins regulating lymphangiogenesis is distinct from those regulating angiogenesis. Importantly, antagonists of these integrins might be useful in preventing tumour metastasis by blocking lymphangiogenesis.
Potential clinical applications
Preclinical studies suggested that antagonists of several integrins might be useful to suppress tumour angiogenesis and growth either alone or in combination with current cancer therapeutics. Although antagonists of several integrins are undergoing preclinical evaluation and development, only a handful of integrin-based drugs have so far been tested in the clinic. Integrin antagonists include function-blocking antibodies, peptides and organic small molecules. Function-blocking anti-integrin monoclonal antibodies typically have high affinity and specificity and have been well-characterized for years. These were the first integrin antagonists to reach the clinic. Cyclic peptide antagonists have also been evaluated in clinical trials. Small organic inhibitors, particularly orally active drugs, are the most costeffective therapeutics but the development of selective and high-affinity integrin inhibitors is time-consuming. Hence, no organic small-molecule antagonists of integrins have yet entered clinical trials (see Integrin inhibitors: rationale for development and clinical results in patients with solid tumors (Ronald M. Bukowski) URL in Further information).
of the several integrin antagonists undergoing clinical evaluation for cancer treatment, all have proved non-toxic, including MEDI-522 (Abegrin), a humanized anti-αvβ3 antibody, CNTo 95, a human αvβ3/αvβ5 antibody, M200 (volociximab), a chimeric mousehuman anti-α5β1 antibody, cilengitide, a cyclic peptide inhibitor of integrins αvβ3 and αvβ5, and ATN-161, a non-RGD-based peptide inhibitor of α5β1 (TABLE 2) . These agents are probably non-toxic because the targeted integrins are only expressed or activated in remodelling tissues such as tumours.
Abegrin, or MEDI-522, was the first anti-integrin therapeutic to be tested in clinical trials for cancer. It is a humanized version of the anti-integrin αvβ3 monoclonal antibody LM609, which has been shown to block tumour angiogenesis by inducing apoptosis in newly formed endothelial cells. A phase I study showed that the early version of this drug, Vitaxin, had low toxicity and was well-tolerated [93] [94] . When tested on patients with metastatic cancer who had failed other treatments, Vitaxin led to disease stabilization without toxicity. However, in a second clinical trial, use of Vitaxin on patients with leiomyosarcoma did not suggest anti-tumour activity. In 2001, Medimmune began clinical trials using Vitaxin (renamed MEDI-522 and Abegrin) and in 2003 initiated phase II trials in patients with advanced metastatic melanoma and in patients with metastatic prostate cancer 95 . In one melanoma trial, 112 patients with stage IV melanoma received 8 mg/kg MEDI-522 each week. of these patients, 57 also received 1,000 mg/m 2 dacarbazine once every 3 weeks and the rest (n = 55) did not. The overall survival was 12.7 months for MEDI-522 plus dacarbazine and 9.4 months for MEDI-522 alone. Both groups showed prolonged survival compared with a historical control 95 . A recent study in patients showed that MEDI-522 had functional efficacy by reducing FAK activity in blood vessels 96 . Based on these results, phase III cancer clinical trials are being planned. on the basis of preclinical studies showing that both integrins αvβ3 and αvβ5 regulate angiogenesis, a human monoclonal antibody directed against both αvβ3 and αvβ5 integrins, CNTo 95, was developed by Centocor. CNTo 95 reduced angiogenesis and tumour growth in human melanoma xenografts in nude mice and rats 97 . Preclinical safety studies on cynomolgus macaques (Macaca fascicularis) showed no toxicity 98 . This antibody has completed phase I safety trials with a favourable safety profile, extended treatment offered to one-third of patients and one patient exhibiting a partial response 99 . CNTo 95 is now under evaluation in a phase I/II clinical trial for the treatment of melanoma (see URL in Further Another drug in clinical trials, ATN-161, is a peptide inhibitor of integrin α5β1. In animal models of colon cancer, ATN-161 reduced metastases and improved survival when combined with chemotherapy 108 . In phase I safety trials, ATN161 was well-tolerated and several patients exhibited stable disease. ATN-161 is currently in phase II clinical trials for multiple myeloma and other tumours 109 . Thus, these two integrin α5β1-inhibiting drugs might offer future benefit to cancer patients.
However, as many integrins can promote angiogenesis, it is not yet clear whether targeting one or more than one will have the most significant effect on tumour angiogenesis and growth. It is also likely that integrin antagonists could be efficacious when combined with other angiogenesis inhibitors such as VEGF inhibitors like Avastin.
Integrin-targeted tumour imaging and treatment.
Integrin ligands are also under investigation as tumour endothelium-targeted diagnostic agents. Both peptide and antibody-based diagnostic agents targeting RGD-binding integrins or αv integrins have been evaluated in animal models of cancer. PEGylated cyclic RGD peptides labelled with 18 F or 64 Cu were effective in imaging xenograft brain and breast tumours with a low signal-to-noise ratio. These imaging approaches have been able to identify xenograft tumours as small as 1.5 mm in diameter [110] [111] . Paramagnetic polymerized liposomes conjugated to an anti-αvβ3 antibody were also used to detect neovascular tumours in experimental rabbit tumours 112 . Integrin αv-targeted ultrasound microbubbles also preferentially bound neovasculature at the periphery of experimental tumours 113 . Thus integrin targeting is proving useful in tumour imaging. It is possible that agents targeting distinct integrins may be useful in pre-classifying patients for receipt of anti-integrin drugs.
Integrin-targeting agents might also be useful in selectively delivering chemotherapeutics or gene therapeutic agents to tumours, thus minimizing global toxicities. For example, an integrin αvβ3-and αvβ5-targeted liposome
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Microbubbles
Small (≥3 µm) gas-filled bubbles that serve as contrastenhancing agents in diagnostic medical ultrasound imaging. information). As CNTo 95 inhibits both integrins αvβ3 and αvβ5, two of the integrins that promote tumour angiogenesis, it might have widespread clinical utility. Additionally, most carcinoma cells express integrin αvβ5, which has been shown to promote tumour cell invasion 100 . Targeting the αv integrins might thus block both tumour cell invasion and metastasis and tumour angiogenesis.
For these reasons, a cyclic RGD-peptide antagonist of αvβ3 and αvβ5, cilengitide (EMD 121974), has been developed as a cancer therapeutic. Phase I clinical trials showed favourable safety profiles and no dose-limiting toxicities 101 (see Cilengitide clinical trial URL in Further information). In addition, cilengitide was shown to enhance radiotherapy in cancer patients 102 . This drug was evaluated in phase I/IIa clinical trials for glioblastoma and significantly increased progression-free survival was observed 101 . on this basis, as of 2007, E. Merck was planning to evaluate cilengitide in phase III trials for glioblastoma. Cilengitide is currently in phase II trials for glioblastoma, non-small cell lung cancer, melanoma and pancreatic cancer [103] [104] [105] . Therefore, three distinct αv integrin-targeting drugs offer promise as cancer therapeutics.
As β1 integrins also have significant roles in angiogenesis, targeting these integrins in addition to αv integrins could be beneficial in suppressing angiogenesis and tumour growth. Antagonists of one integrin, α5β1, have undergone clinical testing. A chimeric mouse-human anti-α5β1 antibody, M200 (volociximab), developed by Protein Design Lab and now partnered with Biogen-Idec Pharmaceuticals, has shown low toxicity in phase I studies. M200 was evaluated in phase II trials for metastatic melanoma, renal cell carcinoma and non-small cell lung cancer [106] [107] . In renal cell carcinoma studies, M200 was well-tolerated at a dose of 10 mg/kg every 2 weeks and stable disease was noted in 87% of patients. In a melanoma trial in combination with dacarbazine, the antibody was well-tolerated and anti-tumour activity was noted in 62% of patients. (nanoparticles) was used to deliver a mutant Raf construct to tumours in animals; this Raf construct induced endothelial cell apoptosis and subsequent tumour suppression 114 . Integrins have thus also proved to be effective targets for delivery of imaging and therapeutic agents.
Conclusions
Blood and lymphatic vessels have crucial roles in promoting tumour growth and metastasis. A substantial body of experimental evidence indicates that integrins regulate endothelial cell migration and survival during angiogenesis and lymphangiogenesis. In addition, integrins promote monocyte trafficking to tumours and subsequent angiogenesis and lymphangiogenesis. As angiogenesis promotes tumour growth and metastasis and lymphangiogenesis promotes tumour metastasis by providing conduits for tumour escape through the lymphatic system, antagonists of these integrins might be useful in blocking tumour metastasis in patients.
Although there is much experimental evidence supporting roles for integrins in tumour angiogenesis and lymphangiogenesis, conflicts between integrin knockout and in vivo tumour studies need to be resolved in the future. Why do many integrin deletion mutants develop normally yet exhibit altered tumour angiogenesis? Future comparisons of embryonic and tumour angiogenesis will address whether compensatory molecular changes occur in surviving mutant animals or whether there are quantitative but non-lethal changes in blood vessel densities in mutant animals.
As several integrin-targeted therapeutic agents are in clinical trials for cancer therapy, future clinical studies will probably determine whether integrin inhibitors will be best used against select tumours, such as those in which tumour cells express the targeted integrin. In addition, integrin-targeted nanoparticles will continue to be developed for the imaging of tumour vasculature and delivery of gene therapy or chemotherapeutic drugs. As integrins are clearly a family of crucial and fundamental regulators of angiogenesis and lymphangiogenesis, the future of integrin antagonists in cancer therapy is promising.
